{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:31:24Z","timestamp":1792697484207,"version":"4.5.0"},"reference-count":104,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T00:00:00Z","timestamp":1585872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2020.00178","type":"journal-article","created":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T00:28:47Z","timestamp":1585873727000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":378,"title":["GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials"],"prefix":"10.3389","volume":"11","author":[{"given":"Matthew P.","family":"Gilbert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Pratley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,4,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1210\/jcem-63-2-492","article-title":"Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses","volume":"63","author":"Nauck","year":"1986","journal-title":"J Clin Endocrinol Metab."},{"key":"B2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/BF02427280","article-title":"Reduced incretin effect in type 2 (non-insulin-dependent) diabetes","volume":"29","author":"Nauck","year":"1986","journal-title":"Diabetologia."},{"key":"B3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s00125-010-1896-4","article-title":"Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?","volume":"54","author":"Nauck","year":"2011","journal-title":"Diabetologia."},{"key":"B4","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s00125-013-2841-0","article-title":"Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies","volume":"56","author":"Calanna","year":"2013","journal-title":"Diabetologia."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/0016-5085(85)90211-2","article-title":"Human distribution and release of a putative new gut hormone, peptide YY","volume":"89","author":"Adrian","year":"1985","journal-title":"Gastroenterology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00125-004-1342-6","article-title":"Incretins, insulin secretion and Type 2 diabetes mellitus","volume":"47","author":"Vilsboll","year":"2004","journal-title":"Diabetologia."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet."},{"key":"B8","doi-asserted-by":"publisher","first-page":"902","DOI":"10.2337\/diab.38.7.902","article-title":"Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)-amide","volume":"38","author":"Komatsu","year":"1989","journal-title":"Diabetes."},{"key":"B9","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/BF00401145","article-title":"Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients","volume":"36","author":"Nauck","year":"1993","journal-title":"Diabetologia."},{"key":"B10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1210\/jcem.81.1.8550773","article-title":"Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients","volume":"81","author":"Willms","year":"1996","journal-title":"J Clin Endocrinol Metab."},{"key":"B11","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1093\/ajcn\/68.3.525","article-title":"Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men","volume":"68","author":"Naslund","year":"1998","journal-title":"Am J Clin Nutr."},{"key":"B12","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/sj.ijo.0801627","article-title":"The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity","volume":"25","author":"Flint","year":"2001","journal-title":"Int J Obes Relat Metab Disord."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1210\/jcem.87.3.8355","article-title":"Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers","volume":"87","author":"Nauck","year":"2002","journal-title":"J Clin Endocrinol Metab."},{"key":"B14","doi-asserted-by":"publisher","first-page":"E199","DOI":"10.1152\/ajpendo.00545.2003","article-title":"Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans","volume":"287","author":"Holst","year":"2004","journal-title":"Am J Physiol Endocrinol Metab."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.2337\/db09-1414","article-title":"The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action","volume":"59","author":"Hare","year":"2010","journal-title":"Diabetes."},{"key":"B16","doi-asserted-by":"publisher","first-page":"E981","DOI":"10.1152\/ajpendo.1997.273.5.E981","article-title":"Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans","volume":"273","author":"Nauck","year":"1997","journal-title":"Am J Physiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s00125-002-0878-6","article-title":"Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients","volume":"45","author":"Vilsboll","year":"2002","journal-title":"Diabetologia."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.2337\/db10-1332","article-title":"GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes","volume":"60","author":"Mentis","year":"2011","journal-title":"Diabetes."},{"key":"B19","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/j.1432-1033.1993.tb17986.x","article-title":"Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum","volume":"214","author":"Mentlein","year":"1993","journal-title":"Eur J Biochem."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1210\/jc.2002-021479","article-title":"Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans","volume":"88","author":"Vahl","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"key":"B21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.bbapap.2005.05.010","article-title":"Type 2 diabetes\u2013therapy with dipeptidyl peptidase IV inhibitors","volume":"1751","author":"Demuth","year":"2005","journal-title":"Biochim Biophys Acta."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13300-014-0061-3","article-title":"Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison","volume":"5","author":"Craddy","year":"2014","journal-title":"Diabetes Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1002\/dmrr.1114","article-title":"Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus","volume":"26","author":"Scheen","year":"2010","journal-title":"Diabetes Metab Res Rev."},{"key":"B24","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1001\/jama.298.2.194","article-title":"Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis","volume":"298","author":"Amori","year":"2007","journal-title":"JAMA."},{"key":"B25","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.beem.2009.03.008","article-title":"Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)\u2013preclinical and clinical results","volume":"23","author":"Madsbad","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab."},{"key":"B26","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.diabres.2010.07.006","article-title":"DPP-4 inhibitors: what may be the clinical differentiators?","volume":"90","author":"Gerich","year":"2010","journal-title":"Diabetes Res Clin Pract."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1089\/dia.2011.0076","article-title":"Exenatide once-weekly clinical development: safety and efficacy across a range of background therapies","volume":"13","author":"Stonehouse","year":"2011","journal-title":"Diabetes Technol Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol Rev."},{"key":"B29","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nat Rev Endocrinol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"key":"B31","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s13300-015-0127-x","article-title":"Comparison review of short-acting and long-acting glucagon-like peptide-1 receptor agonists","volume":"6","author":"Uccellatore","year":"2015","journal-title":"Diabetes Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"CD006423","DOI":"10.1002\/14651858.CD006423.pub2","article-title":"Glucagon-like peptide analogues for type 2 diabetes mellitus","volume":"10","author":"Shyangdan","year":"2011","journal-title":"Cochrane Database Syst Rev."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes","volume":"27","author":"Buse","year":"2004","journal-title":"Diabetes Care."},{"key":"B34","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/j.1463-1326.2007.00744.x","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin","volume":"9","author":"Hermansen","year":"2007","journal-title":"Diabetes Obes Metab."},{"key":"B35","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.3949\/ccjm.76.s5.05","article-title":"Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors","volume":"5","author":"Davidson","year":"2009","journal-title":"Cleve Clin J Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1464-5491.2009.02666.x","article-title":"Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)","volume":"26","author":"Marre","year":"2009","journal-title":"Diabetes Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1016\/S0140-6736(10)60406-0","article-title":"Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial","volume":"375","author":"Diamant","year":"2010","journal-title":"Lancet."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1210\/jc.2010-2081","article-title":"DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes","volume":"96","author":"Blevins","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.2337\/dc13-2760","article-title":"Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1)","volume":"37","author":"Wysham","year":"2014","journal-title":"Diabetes Care."},{"key":"B40","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2337\/dc17-0417","article-title":"Efficacy and safety of once-weekly semaglutide versus exenatide er in subjects with type 2 diabetes (SUSTAIN 3): A 56-week, open-label, randomized clinical trial","volume":"41","author":"Ahmann","year":"2018","journal-title":"Diabetes Care."},{"key":"B41","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1185\/03007990802418851","article-title":"Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study","volume":"24","author":"DeFronzo","year":"2008","journal-title":"Curr Med Res Opin."},{"key":"B43","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1111\/j.1463-1326.2011.01428.x","article-title":"Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study","volume":"13","author":"Berg","year":"2011","journal-title":"Diabetes Obes Metab."},{"key":"B44","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S0140-6736(10)60590-9","article-title":"Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial","volume":"376","author":"Bergenstal","year":"2010","journal-title":"Lancet."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/S0140-6736(10)60307-8","article-title":"Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial","volume":"375","author":"Pratley","year":"2010","journal-title":"Lancet."},{"key":"B46","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jcte.2014.03.001","article-title":"Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus","volume":"1","author":"Van Gaal","year":"2014","journal-title":"J Clin Transl Endocrinol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s13300-012-0013-8.","article-title":"Efficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial)","volume":"3","author":"Bergenstal","year":"2012","journal-title":"Diabetes Ther."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.2337\/dc14-0024","article-title":"HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin","volume":"37","author":"Ahren","year":"2014","journal-title":"Diabetes Care."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.2337\/dc13-2855","article-title":"Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study","volume":"37","author":"Leiter","year":"2014","journal-title":"Diabetes Care."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.2337\/dc13-2761","article-title":"Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5)","volume":"37","author":"Nauck","year":"2014","journal-title":"Diabetes Care."},{"key":"B51","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1111\/dom.12479","article-title":"Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study","volume":"17","author":"Weinstock","year":"2015","journal-title":"Diabetes Obes Metab."},{"key":"B52","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial","volume":"5","author":"Ahren","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1111\/j.1463-1326.2012.01618.x","article-title":"Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)","volume":"14","author":"Seino","year":"2012","journal-title":"Diabetes Obes Metab."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1001\/jama.2019.2942","article-title":"Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"B55","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1210\/jc.2002-021545","article-title":"Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes","volume":"88","author":"Kolterman","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"key":"B56","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.clpt.2005.09.002","article-title":"Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses","volume":"78","author":"Herman","year":"2005","journal-title":"Clin Pharmacol Ther."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.2337\/diacare.25.8.1398","article-title":"Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects","volume":"25","author":"Elbrond","year":"2002","journal-title":"Diabetes Care."},{"key":"B58","doi-asserted-by":"publisher","first-page":"4810","DOI":"10.1210\/jc.2008-1518","article-title":"Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes","volume":"93","author":"Matthews","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.2337\/dc09-0366","article-title":"Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing","volume":"32","author":"Rosenstock","year":"2009","journal-title":"Diabetes Care."},{"key":"B60","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/j.1463-1326.2011.01365.x","article-title":"LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects","volume":"13","author":"Barrington","year":"2011","journal-title":"Diabetes Obes Metab."},{"key":"B61","doi-asserted-by":"publisher","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J Med Chem."},{"key":"B62","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1055\/s-0035-1559654","article-title":"Oral delivery of therapeutic proteins and peptides: an overview of current technologies and recommendations for bridging from approved intravenous or subcutaneous administration to novel oral regimens","volume":"66","author":"Philippart","year":"2016","journal-title":"Drug Res."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2017.14752","article-title":"Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial","volume":"318","author":"Davies","year":"2017","journal-title":"JAMA."},{"key":"B64","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/S2213-8587(19)30194-9","article-title":"Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial","volume":"7","author":"Pieber","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.2337\/diabetes.53.5.1187","article-title":"One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes","volume":"53","author":"Degn","year":"2004","journal-title":"Diabetes."},{"key":"B66","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.2337\/dc06-0703","article-title":"Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes","volume":"29","author":"Aschner","year":"2006","journal-title":"Diabetes Care."},{"key":"B67","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3810\/pgm.2009.05.1998","article-title":"Insights from the liraglutide clinical development program\u2013the liraglutide effect and action in diabetes (LEAD) studies","volume":"121","author":"McGill","year":"2009","journal-title":"Postgrad Med."},{"key":"B68","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1111\/j.1464-5491.2011.03301.x","article-title":"DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide","volume":"28","author":"Wysham","year":"2011","journal-title":"Diabet Med."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.2337\/dc11-2113","article-title":"Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial","volume":"35","author":"Pratley","year":"2012","journal-title":"Diabetes Care."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1111\/dom.12736","article-title":"Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial","volume":"18","author":"Bailey","year":"2016","journal-title":"Diabetes Obes Metab."},{"key":"B71","doi-asserted-by":"publisher","first-page":"e417","DOI":"10.1111\/j.1464-5491.2012.03624.x.","article-title":"A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with type 2 diabetes experiencing inadequate glycaemic control on metformin and sitagliptin","volume":"29","author":"Violante","year":"2012","journal-title":"Diabet Med."},{"key":"B72","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/dom.12802.","article-title":"Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes","volume":"19","author":"Nauck","year":"2017","journal-title":"Diabetes Obes Metab."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med."},{"key":"B75","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med."},{"key":"B76","doi-asserted-by":"publisher","first-page":"14","DOI":"10.2337\/dci17-0057","article-title":"Cardiovascular outcomes trials in type 2 diabetes: where do we go from here?","volume":"41","author":"Cefalu","year":"2018","journal-title":"Diabetes Care."},{"key":"B77","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute Coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med."},{"key":"B81","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet."},{"key":"B82","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med."},{"key":"B83","doi-asserted-by":"publisher","first-page":"i2231","DOI":"10.1136\/bmj.i2231","article-title":"Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis","volume":"353","author":"Salvo","year":"2016","journal-title":"BMJ."},{"key":"B84","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/j.1463-1326.2010.01350.x","article-title":"Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial","volume":"13","author":"Del Prato","year":"2011","journal-title":"Diabetes Obes Metab."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1111\/j.1463-1326.2012.01610.x","article-title":"Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis","volume":"14","author":"Goossen","year":"2012","journal-title":"Diabetes Obes Metab."},{"key":"B86","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.2337\/dc06-0706","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone","volume":"29","author":"Charbonnel","year":"2006","journal-title":"Diabetes Care."},{"key":"B87","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1007\/s00125-006-0416-z","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus","volume":"49","author":"Raz","year":"2006","journal-title":"Diabetologia."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1016\/j.clinthera.2006.10.007","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"28","author":"Rosenstock","year":"2006","journal-title":"Clin Ther."},{"key":"B89","doi-asserted-by":"publisher","first-page":"890","DOI":"10.2337\/dc06-1732","article-title":"Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin","volume":"30","author":"Bosi","year":"2007","journal-title":"Diabetes Care."},{"key":"B90","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/ijcp.12361","article-title":"GLP-1 receptor agonists vs","volume":"68","author":"Brunton","year":"2014","journal-title":"Int J Clin Pract."},{"key":"B91","doi-asserted-by":"publisher","first-page":"k872","DOI":"10.1136\/bmj.k872","article-title":"Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study","volume":"360","author":"Abrahami","year":"2018","journal-title":"BMJ."},{"key":"B92","doi-asserted-by":"publisher","first-page":"377","DOI":"10.4158\/EP13076.LT","article-title":"DPP-IV inhibitor-associated arthralgias","volume":"19","author":"Chaicha-Brom","year":"2013","journal-title":"Endocr Pract."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1002\/pds.3503","article-title":"Association of musculoskeletal complaints and gliptin use: review of spontaneous reports","volume":"22","author":"Tarapues","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B94","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/dmrr.499","article-title":"Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes","volume":"20","author":"Fineman","year":"2004","journal-title":"Diabetes Metab Res Rev."},{"key":"B95","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.2337\/dc14-0001","article-title":"Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro","volume":"37","author":"Rosenstock","year":"2014","journal-title":"Diabetes Care."},{"key":"B96","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1056\/NEJMp1314078","article-title":"Pancreatic safety of incretin-based drugs\u2013FDA and EMA assessment","volume":"370","author":"Egan","year":"2014","journal-title":"N Engl J Med."},{"key":"B97","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.2337\/dc08-1309","article-title":"Exenatide-associated ischemic renal failure","volume":"32","author":"Weise","year":"2009","journal-title":"Diabetes Care."},{"key":"B98","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s11096-010-9423-8","article-title":"Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers","volume":"32","author":"Lopez-Ruiz","year":"2010","journal-title":"Pharm World Sci."},{"key":"B99","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1002\/PHAR.1014","article-title":"Liraglutide-induced acute kidney injury","volume":"32","author":"Kaakeh","year":"2012","journal-title":"Pharmacotherapy."},{"key":"B100","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/j.1464-5491.2012.03738.x","article-title":"Acute tubulointerstitial nephritis following treatment with exenatide","volume":"30","author":"Nandakoban","year":"2013","journal-title":"Diabet Med."},{"key":"B101","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1475-2840-12-53","article-title":"Sitagliptin pretreatment in diabetes patients presenting with acute coronary syndrome: results from the Acute Coronary Syndrome Israeli Survey (ACSIS)","volume":"12","author":"Leibovitz","year":"2013","journal-title":"Cardiovasc Diabetol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2337\/dc10-2415","article-title":"Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes","volume":"34","author":"Wing","year":"2011","journal-title":"Diabetes Care."},{"key":"B103","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.numecd.2007.12.005","article-title":"Clinical and socio-economic correlates of quality of life and treatment satisfaction in patients with type 2 diabetes","volume":"19","author":"Nicolucci","year":"2009","journal-title":"Nutr Metab Cardiovasc Dis."},{"key":"B104","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/j.1742-1241.2011.02656.x","article-title":"One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial","volume":"65","author":"Pratley","year":"2011","journal-title":"Int J Clin Pract."}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2020.00178\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T00:28:50Z","timestamp":1585873730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2020.00178\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,3]]},"references-count":104,"alternative-id":["10.3389\/fendo.2020.00178"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2020.00178","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,3]]},"article-number":"178"}}